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Aims.T h eSLC2A9 gene encodes the glucose transporter 9, with the abilities of transporting both glucose and uric acid and is
involvedinthepancreaticglucose-stimulatedinsulinsecretion.Thesinglenucleotidepolymorphisms(SNPs)ofSLC2A9accounted
for 5% variance of serum uric acid (UA). UA was identiﬁed as a risk factor for type 2 diabetes mellitus (DM). We investigated
whether theSLC2A9 genevariationsare associatedwithtype 2DMinHanChinese.Methods.Three commonSNPsofthe SLC2A9,
rs1014290, rs2280205, and rs3733591, were genotyped in 1003 Han Chinese randomly selected from Kaohsiung, Taiwan. Results.
The variant SNP rs1014290is associated with decreased 0.12-fold risk of type 2 DM (P = .002). Per-copy increase in the minor C-
allele results in 0.13mmol/L (P = .037) and 10.03μmol/L (P = .016) decrease in serum glucose and UA, respectively. Conclusions.
The SNP rs1014290 within the SLC2A9 gene is associated with type 2 DM in Han Chinese.
1.Introduction
T y p e2d i a b e t e sm e l l i t u s( D M ) ,c h a r a c t e r i z e db yi n s u l i n
resistance and relative insulin deﬁciency,is a complex disease
with contributions from both genetic and environmental
factors. Serum uric acid (UA) was associated with insulin
resistance and also a risk factor for development of type 2
DM [1–5]. Meta-analysis showed that the pooled relative
risk of a 1mg/dL increase in UA was 1.17 for incident type
2D M[ 5]. In the animal model, elevated UA level may
worsen insulin resistance by inhibition of the bioavailability
of nitric oxide, which is one of the essential components of
insulin-stimulated glucoseuptake[6].The geneticinﬂuences
outweighed the environmental factors in the estimation of
serum UA by 63–73% [7, 8], with total genetic variability
accounted for 5% of UA variance [9]. The common variants
of SLC2A9 gene have a signiﬁcant role in the UA level, which
accounted for 5-6% and 1-2% variables in the female and
male, respectively.
The SLC2A9 gene encodes the solute carrier family 2,
facilitated glucose transporter member 9 (GLUT9), initially
identiﬁed by sequence similarity with members of the
glucose transporter (Glut) family [10]. The function of
GLUT9 isahigh-capacityuricacid transporter inadditionto
a glucose transporter [11–14]. Furthermore, GLUT9 aﬀected
glucose-stimulated insulin secretion in the pancreatic β cell
and can be upregulated in the diabetic mouse [15, 16].
Due to the GLUT9’s dual capabilities of uric acid
and glucose transportations, we proposed that the SLC2A9
variations might be associated with type 2 DM. In this study,
we investigated three common single nucleotide polymor-
phisms (SNP)of the SLC2A9 gene and their association with
t y p e2D Mi nt h eH a nC h i n e s e .
2.Method
2.1. Study Participants. A cross-sectional survey was per-
formed from one million population of Kaohsiung County,2 Experimental Diabetes Research
Table 1: Clinical characteristics stratiﬁed by sex and DM of enrolled subjects.
Stratiﬁcation Sex P value DM P value
Male Female Non-DM DM
Subject No. 484 519 923 80
Age (years) 49.0 ±0.84 7 .6 ±0.7 .236 47.1 ±0.66 2 .5 ± 1.3 <.001
Sex (male%) — — — 48.6% 43.8% .245
BMI (kg/m2)2 4 .7 ±0.22 3 .5 ±0.2 <.001 23.9 ±0.12 5 .3 ± 0.6 .013
MBP (mmHg) 98.5 ±1.09 2 .0 ±0.7 <.001 94.0 ±0.5 107.9 ±4.3 .002
Glucose (mmol/L) 4.85 ±0.07 4.84 ±0.07 .985 4.55 ±0.02 5.99 ± 0.35 <.001
Uric Acid (μmol/L) 410.4 ±6.0 303.3 ±6.0 <.001 350.9 ±5.9 380.7 ± 11.9 .067
Hemoglobin (g/L) 150.8 ±0.6 132.3 ±0.6 <.001 141.1 ±0.5 141.9 ±1.5 .678
Cholesterol (mmol/L) 4.97 ±0.04 5.08 ±0.04 .066 5.01 ±0.03 5.25 ± 0.12 .036
Triglyceride (mmol/L) 1.55 ±0.06 1.24 ±0.04 <.001 1.32 ±0.03 2.21 ± 0.18 <.001
HDL (mmol/L) 1.41 ±0.02 1.68 ±0.02 <.001 1.57 ±0.01 1.31 ± 0.04 <.001
LDL (mmol/L) 3.14 ±0.04 3.10 ±0.04 .513 3.10 ±0.03 3.30 ± 0.11 .048
eGFR (mL/s) 1.38 ±0.02 1.30 ±0.02 <.001 1.36 ±0.02 1.08 ± 0.05 <.001
Type 2 DM (%) 7.2% 8.7% .401 — — —
Hypertension (%) 17.9% 14.7% .169 14.0% 42.5% <.001
Metabolic syndrome (%) 10.1% 11.8% .235 7.5% 51.3% <.001
Cardiovascular disease (%) 4.8% 5.4% .382 4.9% 7.5% .219
Cerebrovascular disease (%) 1.5% 0.8% .233 1.0% 2.5% .219
Gout (%) 10.4% 2.1% <.001 5.9% 8.8% .211
Minor allele frequency
rs1014290 44.3% 40.1% .011 43.3% 28.8% <.001
rs2280205 22.5% 23.0% .576 22.5% 25.0% .266
rs3733591 34.6% 33.6% .245 33.5% 40.6% .179
Values are expressed as mean ± SEM or percentage.
The P values were determined from t-tests for continuous variables and from Pearson chi-square test, and ﬁsher’s exact test for categorical variables.
Abbreviations:BMI: body massindex,MBP: meanblood pressure,HDL: high-densitylipoprotein, LDL: low-densitylipoprotein, eGFR:estimatedglomerular
ﬁlatration rate, DM: diabetes mellitus.
Taiwan. Twelve villages were randomized selected from
twenty-seven villages with a total of 1003 subjects sampled
through multistage stratiﬁed approaches between April 2007
andJanuary 2008.Height,bodyweight,abdominalgirth,and
blood pressure were measured at the screen day. All clinical
information including underlying diseases, drug history, and
social habits were accomplished by trained persons via a
standard questionnaire according to the subject’s statement.
Aborigines and foreigners were excluded from this survey.
The type 2 DM was diagnosed by the subject’s statement and
serum glucose above 7mmol/L (126mg/dL).
2.2. Genotype Analysis. Three SNPs (rs2280205, rs1014290,
and rs3733591) of the SLC2A9 gene were selected for
genotype analysis with minor allele frequency >20% in Han
Chinese (accordingtoHapMapdata).These three SNPs were
reported to be associated with uric-acid-related phenotypes,
such as gout and tophus formation [13, 17]. DNA was col-
lected from the peripheral blood leukocytes and genotyping
was performed by the TaqMan SNP allelic discrimination
assay with an ABI 7900HT Sequence Detection System [18].
2.3. Statistical Analysis. The diﬀerences of clinical character-
istics between sexes, diabetes, and genotypes were analyzed
by Student’s t-test, Pearson’s Chi-square test, Fisher’s exact
test, and analysis of variance (ANOVA). The genotype
and allele frequencies for Hardy-Weinberg equilibrium pro-
portions were tested by Pearson’s Chi-square test. Linear
regression was used to investigate the changes in uric acid
and serum glucose for per-copy increment in the minor
allele. Binary logistic regression was used to evaluate the
risk of type 2 DM between genotype groups. Statistical
analyses were performed with SPSS version 18. P values
lessthan .05wereconsideredstatisticallysigniﬁcant.Subjects
were analyzed by sex stratiﬁcation to evaluate the gender
inﬂuence of the SLC2A9 on type 2 DM, since the SLC2A9
has a female-predominant eﬀect on UA level.
3.Result
The minor allele frequencies of the investigated SNPs were
42.1% for rs1014290, 22.7% for rs2280205, and 34.1%
for rs3733591. These genotype frequencies were similar to
the Han Chinese of the Hapmap database and all were
in agreement with the Hardy-Weinberg equilibrium. All
three loci are not in linkage. The demographic and clinical
characteristics of study participants stratiﬁed by sex and DM
were shown in Table 1. In the sex stratiﬁcation, female had
lowerbodymass index(BMI),meanarterialpressure(MBP),Experimental Diabetes Research 3
Table 2: Clinical characteristics stratiﬁed by rs1014290 C/T polymorphism in both sex in the SLC2A9 gene.
Male P value Female P value
TT CT CC TT CT CC
Subjects No. 147 245 92 177 268 74
Age (years) 49.9 ±1.54 8 .1 ± 1.24 8 .1 ±1.9 .617 47.6 ±1.34 7 .6 ±1.04 9 .8 ±1.8 .582
BMI (kg/m2)2 4 .8 ±0.32 4 .7 ± 0.42 4 .2 ±0.4 .651 23.8 ±0.32 3 .5 ±0.32 3 .2 ±0.5 .625
MBP (mmHg) 101.5 ±2.69 7 .7 ± 0.99 4 .3 ±1.5 .032 92.8 ±1.19 2 .4 ±0.99 0 .6 ±1.6 .580
Glucose (mmol/L) 4.92 ±0.14 4.79 ± 0.09 4.64 ±0.07 .298 5.17 ±0.17 4.78 ±0.07 4.56 ±0.10 .006
Uric Acid (μmol/L) 410.4 ±6.0 410.4 ± 6.0 398.5 ±11.9 .575 321.2 ±6.0 303.3± 6.0 279.6 ±6.0 .002
Hemoglobin (g/L) 151.9 ±1.1 150.8 ± 0.8 149.0 ±1.5 .269 133.4 ±1.0 132.1± 0.9 130.2 ±1.7 .243
Cholesterol (mmol/L) 5.01 ±0.07 4.97 ± 0.06 4.89 ±0.12 .622 5.16 ±0.08 5.03 ±0.06 5.08 ±0.11 .405
Triglyceride (mmol/L) 1.65 ±0.09 1.46 ± 0.06 1.52 ±0.18 .306 1.32 ±0.07 1.21 ±0.05 1.32 ±0.16 .435
HDL (mmol/L) 1.40 ±0.03 1.44 ± 0.03 1.44 ±0.04 .637 1.67 ±0.03 1.66 ±0.03 1.69 ±0.05 .830
LDL (mmol/L) 3.14 ±0.06 3.15 ± 0.06 3.05 ±0.10 .630 3.17 ±0.07 3.08 ±0.05 3.06 ±0.09 .517
eGFR (mL/s) 1.38 ±0.04 1.40 ± 0.03 1.39 ±0.05 .858 1.32 ±0.03 1.28 ±0.02 1.23 ±0.04 .201
Type 2 DM (%) 9.5% 8.2% 1.1% .036 13.0% 7.5% 2.7% .018
Hypertension (%) 19.0% 17.2% 18.0% .900 16.4% 14.3% 12.2% .655
Metabolic syndrome (%) 11.6% 10.2% 7.6% .614 13.0% 12.3% 6.8% .346
Cardiovascular disease (%) 4.8% 4.1% 6.7% .607 5.7% 4.9% 6.8% .809
Cerebrovascular disease (%) 2.0% 1.2% 1.1% .777 1.1% 0.8% 0.0% .647
Gout (%) 15.1% 8.2% 9.0% .088 3.4% 1.5% 1.4% .356
Values are expressed as mean ± SEM or percentage.
The P values were determined from t-tests for continuous variables and from Pearson chi square test and ﬁsher’s exact test for categorical variables.
Abbreviations: as Table 1.
uric acid, hemoglobin, triglyceride, estimated glomerular
ﬁltration rate (eGFR), and percentage of gout but higher
high-density lipoprotein (HDL). In the DM stratiﬁcation,
the DM subgroup was older and has higher BMI, MBP,
fasting serum glucose, uric acid, cholesterol, triglyceride,
low-density lipoprotein (LDL), and higher percentages of
hypertension and metabolic syndrome but lower HDL and
eGFR than non-DM subgroup. The genotype frequencies of
the SNP rs1014290 were lower in the female and the DM
subgroup.
3.1. Genotype Analysis of Investigated SNPs. The rs1014290
showeddiﬀerentfrequenciesoftype2DMbetweengenotype
groups (Table 2). Lower glucose (P = .006), uric acid (P =
.002),and type 2 DM (P = .019) were found to be associated
with the rs1014290 only in the female but not in the male.
There were no diﬀerences in the other clinical characteristics
between genotype groups.
In all subjects, each copy of SNP rs1014290 minor C-
allele decreased covariate adjusted glucose and uric acid
level by 0.13mmol/L (P = .037) and 10.03μmol/L (P =
.006), respectively. In female subgroup, the decreased eﬀect
of minor C-allele on glucose and uric acid level was
more predominant. Each copy increase of the minor C-
allele resulted in 0.22mmol/L decrease (P = .018) and
18.39μmol/L decrease (P<. 001) in covariate adjusted
glucose level and uric acid level, respectively. The sig-
niﬁcant eﬀect of SNP rs1014290 on glucose and uric
acid level decrease was not replicated in male participants
(Table 3).
Table 3: Glucose and uric acid level diﬀerences for per-copy
increase of minor allele for rs1014290 in the SLC2A9 gene.
Glucose Uric Acid
Unstandardized
coeﬃcient β P value Unstandardized
coeﬃcient β P value
Total
Unadjusted −0.24 .001 −8.17 .080
Adjusted −0.13 .037 −10.03 .006
Male
Unadjusted −0.13 .156 −5.05 .391
Adjusted −0.03 .759 −2.35 .676
Female
Unadjusted −0.34 .002 −19.35 <.001
Adjusted −0.22 .018 −18.39 <.001
Values are expressed as unstandardized coeﬃcient.
The P values were determined from linear regression analysis.
Adjusted for age, eGFR, MBP, cholesterol, triglyceride, HDL, BMI, antidi-
abetic agents and sex in total group (sex was excluded in sex subgroup
analysis)in glucose analysis.
Adjustedforage,eGFR,MBP, cholesterol,triglyceride,HDL, BMI,andsexin
total group (sexwas excludedin sexsubgroup analysis)in uric acid analysis.
In all subjects, each copy of SNP rs1014290 minor C-
allele decreased covariate adjusted glucose and uric acid
level by 0.13mmol/L (P = .037) and 10.03μmol/L (P =
.006), respectively. In the female subgroup, this eﬀect was
more predominant with 0.22mmol/L decrease (P = .018)
and 18.39μmol/L decrease (P<. 001) in covariate adjusted
glucose level and uric acid level, respectively. This eﬀect of4 Experimental Diabetes Research
Table 4: Binary logistic regression analysis for type 2 DM risk.
Unadjusted Adjusted model 1 Adjusted model 2
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Total
rs1014290 variation
TT 1 (Reference) — 1 (Reference) — 1 (Reference) —
CT 0.63 (0.39–1.01) .056 0.66 (0.40–1.09) .101 0.67 (0.39–1.13) .136
CC 0.15 (0.05–0.49) .002 0.15 (0.05–0.51) .002 0.12 (0.03–0.45) .002
Uric acid 1.02 (1.00–1.05) .036 1.01 (0.98–1.04) .389 0.99 (0.96–1.02) .610
Male
rs1014290 variation
TT 1 (Reference) — 1 (Reference) — 1 (Reference) —
CT 0.81 (0.39–1.67) .564 0.85 (0.40–1.79) .672 0.86 (0.37–1.97) .719
CC 0.11 (0.01–0.86) .036 0.12 (0.02–0.94) .043 0.09 (0.01–0.93) .043
Uric acid 1.01 (0.97–1.05) .651 1.00 (0.96–1.04) .944 0.98 (0.94–1.03) .398
Female
rs1014290 variation
TT 1 (Reference) — 1 (Reference) — 1 (Reference) —
CT 0.52 (0.27–0.98) .044 0.53 (0.26–1.05) .069 0.50 (0.24–1.05) .066
CC 0.19 (0.04–0.81) .025 0.17 (0.04–0.76) .021 0.13 (0.02–0.70) .018
Uric acid 1.06 (1.02–1.09) .001 1.01 (0.97–1.05) .533 0.99 (0.95–1.05) .724
Values are expressed as odds ratio (95% conﬁdence interval). For uric acid, odds ratio was expressed for per 10μmol/L increase in level.
The P values were determined from binary logisticregression analysis.
Model1:adjustedforage,BMI,uricacid,thers1014290C/TpolymorphismofSLC2A9gene,andsexintotalgroup(sexwasexcludedinsexsubgroupanalysis).
M o d e l2 :a d j u s t e df o rc o v a r i a t e so fm o d e l1 ,M B P ,c h o l e s t e r o l ,H D L ,L D L ,a n dt r i g l y c e r i d e .
Abbreviations: as Table 1.
SNP rs1014290 on glucose and uric acid level decrease was
not found in the male participants (Table 3).
For all subjects and sex subgroup, the CC group of
SLC2A9 SNP rs1014290 is associated with decreased risk for
prevalent type 2 DM either in unadjusted or in adjusted
model (Table 4). In the total group, compared with the TT
group, the CC group conferred covariate adjusted 0.12-fold
decreased risk of prevalent type 2 DM (95% conﬁdence
interval (CI) = 0.03–0.45, P = .002). In the subgroup
analysis, this eﬀect still existed in both sexes with weaker
association in the male than in the female (male:odds ratio
(OR) = 0.09, 95% CI = 0.01–0.93, P = .043; female: OR
= 0.13, 95% CI = 0.02–0.70, P = .018). In contrary to
the rs1014290 polymorphism, the uric acid only exerts a
signiﬁcant eﬀect on the prevalent type 2 DM in unadjusted
model of total and female group (OR for 10μmol/L increase
in UA level = 1.02, 95% CI = 1.00–1.05, P = .036; OR for
10μmol/L increase in UA level = 1.06, 95% CI = 1.02–1.09,
P<. 001, resp.). The signiﬁcant results of the rs1014290
polymorphism on the prevalent type 2 DM in the adjusted
model suggested that the association between type 2 DM
and SLC2A9 variation is independent from the uric acid
eﬀect.
In the remaining variants of rs2280205 and rs3733591,
nosigniﬁcant eﬀectsontheglucose,UA,and type2DMwere
found (Data not shown).
4.Discussion
We showed that in Han Chinese, the SLC2A9 SNPrs1014290
is relevant to the prevalent of type 2 DM and serum glucose
level in addition to the uric acid level. SNP rs1014290
variation is a nucleotide transversion from T to C located
in the intron 3 of SLC2A9 gene. Its minor allele frequency
in Asian is about 40%, which is higher than the 30% in
Caucasian according to HapMap data. The minor C-allele
of SNP rs1014290 was found to associate with lower UA
level, higher fractional excretion of uric acid and lower
risks for gout and nephrolithiasis [13, 19]. The eﬀect on
decreasing uric acid levelofminor C-allele ofSNPrs1014290
isgreaterinfemalethaninmale.TheinﬂuenceoftheSLC2A9
variation onglucoselevelismorepredominantin thefemale,
as well as uric acid showed in our study and previous reports
[11–14]. In the total group, this female predominant eﬀect
on uric acid is powerful enough to make the insigniﬁcant
unadjusted P value become signiﬁcant in adjusted model.
The P value changed from .075 to .002 when sex was added
as covariate to the unadjusted model. In the Caucasian, the
per copy of minor C-allele contributes to 45.2–50.6μmol/L
(0.76–0.85mg/dL) decrease of serum uric acid level in the
female and 10.1–21.4μmol/L (0.17–0.36mg/dL) decrease in
t h em a l e[ 13]. The eﬀect of minor C-allele on decreas-
ing uric acid level seems to be weaker in Han Chinese.Experimental Diabetes Research 5
In our study, each copy of minor C-allele decreases uric
acid by 19.35μmol/L and 5.05μmol/L in female and in male,
respectively, and this eﬀect is insigniﬁcant in male. Similar
result was found in a recent study including 191 male Han
Chinese from Taiwan, where no inﬂuences ofSNPrs1014290
variation on uric acid level were found [17]. Our data
suggested that the SNP rs1014290 variation in the SLC2A9
is associated with serum uric acid level in the Han Chinese
with female predominance.
GLUT9 was classiﬁed as glucose and/or fructose trans-
porter despitevery low transport activities [20, 21]. Recently,
the GLUT9 was considered as a uric acid transporter rather
than glucose and/or fructose transporter [11–14]. However,
our study showed that the SNP rs1014290 variation is
associated with type 2 DM and serum glucose level (Tables
3 and 4). GLUT9 was found to be upregulated in liver and
kidney tissue in diabetic mouse and aﬀected the glucose-
sensing insulin secretion in pancreatic β cell [15, 16].
Pancreatic β cell was responsible for detecting the change
of blood glucose concentration and modulating insulin
secretion, which consisted of a rapid ﬁrst phase and the
prolonged second phase. The ﬁrst step for the pancreatic
β cell to sense extracellular glucose concentration is the
uptake of glucose by glucose transporter. GLUT9 might be
responsible for this glucose uptake in the prolonged second
phase of insulin secretion. [15] Thus, the minor C-allele
of SNP rs1014290 might exert an inﬂuence on the second
phase of insulin secretion and consequently altered serum
glucose level and type 2 DM development. In our result,
the association between SNP rs1014290 variation and the
prevalence of type 2 DM is independent from the eﬀect of
uric acid.
Uric acid was identiﬁed as a risk factor for the develop-
ment of type 2 DM in other studies [1–5]. But our result
was only signiﬁcant in unadjusted model of total and female
groups (Table 4). This might be due to the older age of our
DM subjects than that of other study subjects. The mean age
of our DM subjects is around 62.5 years which is older than
otherstudysubjects(around40–60years)[5].This suggested
that the age per se and the duration of DM might aﬀect the
association between UA and type 2 DM.
The minor allele frequency of SNP rs2280205 and
SNP rs3733591 in our study is similar with that reported
in Han Chinese group in HapMap data. The association
between uric acid level and variations of SNP rs2280205 and
SNP rs3733591 were reported [11], but the result was not
replicated in our Han Chinese subjects. This may be due
to the minor allele frequencies of SNP rs2280205 and SNP
rs3733591 which are diﬀerent between European and Han
Chinese.
The limitations of this are that our study is lacking the
accurate diagnosis of type 2 DM and only random glucose
level was tested without the measurement of glycosylated
hemoglobin. This might lead to the ﬁnding that the SNP
rs1014290 variation is not associated with serum glucose
level but associated with type 2 DM in the male group. This
contradictory result could also derive from the confound-
ing eﬀect of antidiabetic agents use and the inconsistent
treatment response to DM medication. All these could
confound the interpretation of the genetic eﬀects on type 2
DM risk.
In conclusion, the SNP rs1014290 variation of SLC2A9
gene was associated with type 2 DM and serum glucose
level in addition to uric acid level. The genetic eﬀect on the
association with type 2 DM is independent from the uric
acid eﬀect. This suggested that the SLC2A9 gene may be a
candidate genetic locus for the pathogenesis of type 2 DM.
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